TNFRSF8 and classic Hodgkin lymphoma: A novel anti-CD30 antibody, brentuximab vedotin, was approved by Food and Drug Administration to treat refractory cHL and ALCL in 2011, which throws the light on therapeutic tactics for other CD30 positive lymphomas.